Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients

Abstract

Abrupt cessation of brodalumab is associated with a rapid relapse of psoriasis with some patients experiencing a rebound. It seems not advisable to stop treatment with IL-17 receptor antagonists abruptly even in patients who experience complete clearance of psoriasis.